Table 1.

Acro-TSQ score descriptive summary, second study

Acro-TSQ scale	Statistic	Screening N = 82	Baseline N = 81	Week 26 N = 77
Symptom interference	Mean	72	78	78
	Median	75	81	94
	SD	25	24	27
	Range	19–100	19–100	0–100
	Floor (n, %)	0 (0%)	0 (0%)	1 (1%)
	Ceiling (n, %)	26 (32%)	35 (43%)	38 (49%)
Treatment convenience	Mean	67	68	70
	Median	67	71	71
	SD	21	21	18
	Range	4–100	17–100	17–100
	Floor (n, %)	0 (0%)	0 (0%)	0 (0%)
	Ceiling (n, %)	4 (5%)	5 (6%)	1 (1%)
Injection site interferencea	Mean	84	85
	Median	88	88
	SD	20	18
	Range	13–100	38–100
	Floor (n, %)	0 (0%)	0 (0%)
	Ceiling (n, %)	39 (48%)	40 (49%)
GI interference	Mean	80	84	83
	Median	92	92	100
	SD	24	21	23
	Range	0–100	17–100	25–100
	Floor (n, %)	1 (1%)	0 (0%)	0 (0%)
	Ceiling (n, %)	37 (45%)	39 (48%)	41 (53%)
Treatment satisfaction	Mean	61	61	58
	Median	61	61	61
	SD	20	19	25
	Range	0–100	14–100	0–100
	Floor (n, %)	1 (1%)	0 (0%)	3 (4%)
	Ceiling (n, %)	2 (2%)	3 (4%)	3 (4%)
Emotional reaction	Mean	80	82	84
	Median	83	83	92
	SD	22	20	21
	Range	0–100	0–100	25–100
	Floor (n, %)	2 (2%)	2 (3%)	0 (0%)
	Ceiling (n, %)	23 (28%)	22 (27%)	33 (43%)

Floor is most symptomatic; Ceiling Least Symptomatic. Lower scores indicate greater interference/lower satisfaction; higher score indicate less interference/higher satisfaction

GI gastrointestinal, SD standard deviation

^aInjection site interference scale was not administered at week 26